NEW YORK, NY / ACCESSWIRE / September 28, 2022 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

LFST Shareholders Click Here: https://www.zlk.com/pslra-1/lifestance-health-lawsuit-loss-submission-form?prid=32175&wire=1
DDL Shareholders Click Here: https://www.zlk.com/pslra-1/dingdong-lawsuit-submission-form?prid=32175&wire=1
PLTR Shareholders Click Here: https://www.zlk.com/pslra-1/palantir-lawsuit-loss-submission-form?prid=32175&wire=1

* ADDITIONAL INFORMATION BELOW *

LifeStance Health Group, Inc. (NASDAQ:LFST)

This lawsuit is on behalf of all purchasers of LifeStance common stock pursuant and/or traceable to the documents issued in connection with LifeStance's June 10, 2021 initial public stock offering.
Lead Plaintiff Deadline : October 11, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/lifestance-health-lawsuit-loss-submission-form?prid=32175&wire=1

According to the filed complaint, (i) the number of virtual visits clients were undertaking utilizing LifeStance Health was decreasing as the COVID-19 lockdowns were being lifted, thereby flatlining LifeStance Health's out-patient/virtual revenue growth; (ii) the percentage of in-person visits clients were undertaking utilizing LifeStance Health was increasing as the COVID-19 lockdowns were being lifted, thereby causing LifeStance Health's operating expenses to increase substantially; (iii) LifeStance Health had lost a large number of physicians due to burn-out and, as a result, its physician retention rate had fallen significantly below the 87% highlighted in the initial public offering's registration statement, and LifeStance Health had been expending additional costs to onboard new physicians who were less productive than the outgoing physicians they were replacing; and (iv) as a result, LifeStance Health's business metrics and financial prospects were not as strong as the initial public offering's registration statement represented.

Dingdong (Cayman) Ltd. (NYSE:DDL)

This lawsuit is on behalf of persons who purchased, or otherwise acquired, Dingdong American Depository Shares pursuant or traceable to the F-1 registration statements and related prospectus on Form 424B4 issued in connection with Dingdong's June 2021 initial public stock offering.
Lead Plaintiff Deadline : October 24, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/dingdong-lawsuit-submission-form?prid=32175&wire=1

According to the filed complaint, the registration statement and prospectus used to effectuate the Company's initial public offering misstated and/or omitted facts concerning Dingdong's so-called commitment to ensuring the safety and quality of the food it distributes to the market. For example, despite claiming that it applies 'stringent quality control across [its] entire supply chain to ensure product quality to [its] users,' Dingdong sold food past its sell-by date. Consequently, Dingdong was, in fact, no better at providing or assuring access to 'fresh' groceries than the supermarkets, traditional Chinese wet markets, or traditional e-commerce platforms it repeatedly claimed to be displacing. Moreover, the foregoing conduct subjected Dingdong to an increased risk of regulatory and/or governmental scrutiny and enforcement, all of which, once revealed, were likely to negatively impact Dingdong's business, operations, and reputation.

Palantir Technologies Inc. (NYSE:PLTR)

PLTR Lawsuit on behalf of: investors who purchased November 9, 2021 - May 6, 2022
Lead Plaintiff Deadline : November 14, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/palantir-lawsuit-loss-submission-form?prid=32175&wire=1

According to the filed complaint, during the class period, Palantir Technologies Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Palantir's investments in marketable securities were having a significant negative impact on the Company's earnings per share ('EPS') results; (ii) Palantir overstated the sustainability of its government segment's growth and revenues; (iii) Palantir was experiencing a significant slowdown in revenue growth, particularly among its government customers, despite ongoing global conflicts and market disruptions; (iv) as a result of all the foregoing, the Company was likely to miss consensus estimates for its first quarter 2022 EPS and second quarter 2022 sales outlook; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP